Details of the Drug

General Information of Drug (ID: DMMXU5U)

Drug Name
PBFT02
Indication
Disease Entry ICD 11 Status REF
Frontotemporal dementia 6D83 Phase 1/2 [1]
Drug Type
Gene therapy
Cross-matching ID
TTD ID
D8FX9H

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Progranulin (PGRN) TT4LM0E GRN_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04747431) A Phase 1b Open-Label, Multicenter, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacodynamic Effects of a Single Dose of PBFT02 Delivered Into the Cisterna Magna of Adult Subjects With Frontotemporal Dementia and Mutations in the Progranulin Gene. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Passage Bio